Compare Moderna, Inc. (MRNA) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs WD 40 Company — how do they compare? Moderna, Inc. trades at $136.43 (market cap $56.02B), while WD 40 Company trades at $199.54 (market cap $2.71B). The key difference: Moderna, Inc. is far larger — about 20.7× WD 40 Company's market cap, and WD 40 Company pays a 2.02% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WDFC | |
|---|---|---|
Market Cap | $56.02B | $2.71B |
Sector | Health | Technology |
52-Week High | $174.38 | $264.91 |
52-Week Low | $22.36 | $187.52 |
Enterprise Value | $52.17B | $2.76B |
Dividend Yield | — | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
WDFC trades at $201.73, down 2.81% today, with a bearish technical signal but strong fundamentals. Recent earnings show mixed results with a Q4 2025 miss but Q1 and Q2 2026 beats. The company maintains robust profitability with a 55.82% gross margin and 13.22% net margin. News highlights strong Q3 2026 performance and strategic growth initiatives including global expansion and digital transformation.
Outlook is cautiously optimistic with solid brand loyalty and growth potential, but risks include input cost pressures and valuation concerns. Analyst consensus is mixed with a 'Hold' majority. The stock's current price near support at $199 suggests potential stability if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
